Because market access strategies should be rooted in the truth, not conjecture

We allow biopharma to ask the right people the right questions at the right time

We created Formulary Insights to help biopharmaceutical investors, marketers, and leaders better understand and anticipate payer and specialty pharmacy perceptions of every therapeutic area.

WHAT WE DO

We only provide you with insights from
real decision makers

No retirees,
no loose affiliations,
no misrepresentations 

Business%20handshake_edited.jpg

OUR UNIQUE VALUE PROPOSITION

008-conference.png
OUR PANEL

Only FORMULARY INSIGHTS can identify active market access decision makers

014-fast-delivery.png
OUR SPEED

Actionable insights in weeks not months

003-rating.png
OUR PEOPLE

Insights interpreted only by those who’ve been there before

site_logo.png
Full Color_cmyk_side-by-side - 2157x500.jpg
Full Color_cmyk_side-by-side - 2157x500.jpg
NO RETIREES, NO LOOSE AFFILIATIONS, NO MISREPRESENTATIONS

All our panelists are active decision makers

Business Meeting
Syndicated-Research-Sample_edited.jpg

Do you want to see a sample of our research?

Customized samples available upon request.

OUR MOST POPULAR OFFERINGS

DIRECT INQUIRY

Your opportunity for exhaustive research on key areas of interest
A single-study deep-dive to ensure a complete understanding of payer interests and impressions
home-syndicated-research.jpg

SYNDICATED RESEARCH

All the benefits of our Direct Inquiry studies without the compliance requirements of developing your own

TESTIMONIALS

Pre-launch Study Evaluations gave us the insights that informed Phase 3 study design in time for us to include critical payer endpoints.
With a second indication on the horizon, a therapeutic class Drug Monograph Analysis revealed several unexpected perspectives that we leveraged to protect access.
Pre-launch competitive Label Comparison enabled us to prioritize our label negotiations to ensure our payer value was well represented at launch.
When we launched our small KAM team, we targeted Hospital System panelists to garner system-specific product insights that drove segmentation and prioritization of KAM targeting.
We bought a Rapid Study subscription so that we can put out fires quickly based on feedback from our panelists whenever we need it!
A Formulary Insights Direct Inquiry provided us with the payer insights we needed to make a go or no-go decision on several planned product strategies based on their expected access impact, quickly enhancing our product access and performance.
Imagine a room where America’s most sought-after market access decision makers have gathered for all your questions

We allow biopharma to ask the right people the right questions at the right time